Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Neil Beeharry et al.|Journal of Hematology & Oncology|2018Cited by 56
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Ilaria Iacobucci et al.|Oncotarget|2016Cited by 42
Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cellsAndrea Ghelli Luserna di Rorà, Giorgia Simonetti, Martina Ghetti et al.|Cell Biology and Toxicology|2021Cited by 28
Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic LeukemiaAndrea Ghelli Luserna di Rorà, Giovanni Martinelli, Tim J. Yen et al.|Cancers|2019Cited by 27
Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid LeukemiaAntonella Padella, Giovanni Martinelli, Giorgia Simonetti et al.|Cancers|2019Cited by 24